List of the main criteria for HPD definition
| HPD definition | Drug | Type of tumor | Patients (N) | HPD (%) | Predictive factors | Reference |
|---|---|---|---|---|---|---|
| PD RECIST and increase in TGR ≥ 2 | mAb anti PD-1/PD-L1 (phase I) | Various | 131 | 9% | Age ≥ 65 years | [6] |
| PD RECIST and ΔTGR > 50% | mAb anti PD-1/PD-L1 | NSCLC | 406 | 13.8% | > 2 metastatic sites | [9] |
| PD RECIST & increase in TGR ≥ 2 | CKI and costimulatory molecules | Various | 182 | 7% | Female | [8] |
| Increase in TGK ≥ 2 | mAb anti PD-1/PD-L1 | HNSCC | 34 | 29% | Tumor relapse in RT | [12] |
| PD RECIST and 3 criteria among: 1) TTF < 2 months; 2) increase ≥ 50% in sum of target diameters; 3) ≥ 2 new lesions in already involved organs; 4) Mets in new organs; 5) PS ECOG ≥ 2 | CKI | NSCLC | 152 | 25.7% | Myeloids cell density and MPO in the tumor & low PD-L1 | [14] |
| TTF < 2 months and increase in tumor burden ≥ 50% and increase in pace of growth ≥ 2 | CKI and costimulatory molecules | Various | 155 | 4% | EGFR, MDM2/4, DNMT3A | [10] |
| TTF < 2 months and increase ≥ 10 mm in mesurable lesions and increase ≥ 40% of tumor burden or > 20% with apperance of new lesions | CKI | Various | 214 | 15% | [11] | |
| TTF < 2 months and TGK ≥ 2 and increase in tumor volume ≥ 50% | CKI | NSCLC | 135 | 13.1% | NLR > 4, LDH > UNL, STK11 | [15] |
| PD RECIST and RECIST ≥ 50% and increase in TGR ≥ 2 | CKI | Various | 5 HPD patients | MDM2/4, EGFR | [16] |
PD: progressive disease; PS: performance status; mAb: monoclonal antibody; CKI: cyclin-dependent kinase inhibitors; HNSCC: head and neck squamous cell carcinoma; RT: radiotherapy; MPO: myeloperoxidase; MDM2/4: Mouse double minute 2/4 homolog; DNMT3A: DNA methyltransferase 3 alpha; NLR: neutrophil lymphocyte ratio; LDH: lactate dehydrogenase; UNL: upper normal limit; STK11: Serine/threonine kinase 11
